Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Mak KS, et al. Among authors: gore em. Eur Urol Focus. 2024 Feb 1:S2405-4569(24)00011-7. doi: 10.1016/j.euf.2024.01.008. Online ahead of print. Eur Urol Focus. 2024. PMID: 38307806
5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy.
Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L. Li Q, et al. Among authors: gore em. medRxiv [Preprint]. 2023 Oct 16:2023.10.13.23296758. doi: 10.1101/2023.10.13.23296758. medRxiv. 2023. PMID: 37904926 Free PMC article. Preprint.
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.
Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. Weidhaas JB, et al. Among authors: gore em. Cancer Res Commun. 2023 Oct 11;3(10):2074-2081. doi: 10.1158/2767-9764.CRC-23-0084. Cancer Res Commun. 2023. PMID: 37728512 Free PMC article.
Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy.
Simone CB 2nd, Serebrenik AA, Gore EM, Mohindra P, Brown SL, Wang D, Chetty IJ, Vujaskovic Z, Menon S, Thompson J, Fine G, Kaytor MD, Movsas B. Simone CB 2nd, et al. Among authors: gore em. Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):404-414. doi: 10.1016/j.ijrobp.2023.08.048. Epub 2023 Aug 29. Int J Radiat Oncol Biol Phys. 2024. PMID: 37652301 Free article. Clinical Trial.
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.
Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Spratt DE, et al. Among authors: gore em. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):370-377. doi: 10.1016/j.ijrobp.2023.04.010. Epub 2023 May 2. Int J Radiat Oncol Biol Phys. 2023. PMID: 37137444 Clinical Trial.
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.
Movsas B, Rodgers JP, Elshaikh MA, Martinez AA, Morton GC, Krauss DJ, Yan D, Citrin DE, Hershatter BW, Michalski JM, Ellis RJ, Kavadi VS, Gore EM, Gustafson GS, Schulz CA, Velker VM, Olson AC, Cury FL, Papagikos MA, Karrison TG, Sandler HM, Bruner DW. Movsas B, et al. Among authors: gore em. J Clin Oncol. 2023 Jun 10;41(17):3217-3224. doi: 10.1200/JCO.22.02389. Epub 2023 Apr 27. J Clin Oncol. 2023. PMID: 37104723 Clinical Trial.
Consensus Quality Measures and Dose Constraints for Lung Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and ASTRO Expert Panel.
Puckett LL, Titi M, Kujundzic K, Dawes SL, Gore EM, Katsoulakis E, Park JH, Solanki AA, Kapoor R, Kelly M, Palta J, Chetty IJ, Jabbour SK, Liao Z, Movsas B, Thomas CR Jr, Timmerman RD, Werner-Wasik M, Kudner R, Wilson E, Simone CB 2nd. Puckett LL, et al. Among authors: gore em. Pract Radiat Oncol. 2023 Sep-Oct;13(5):413-428. doi: 10.1016/j.prro.2023.04.003. Epub 2023 Apr 18. Pract Radiat Oncol. 2023. PMID: 37075838
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.
Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, Mishra MV, Roach M 3rd, Parliament MB, Choi KN, Pisansky TM, Husain SM, Malone SC, Horwitz EM, Feng F. Mell LK, et al. Among authors: gore em. Eur Urol. 2024 Apr;85(4):373-381. doi: 10.1016/j.eururo.2023.01.020. Epub 2023 Jan 28. Eur Urol. 2024. PMID: 36710205
47 results